DK155009B - METHOD OF ANALOGUE FOR THE PREPARATION OF THIENOOE2,3-EAA-1,2-THIAZIN-1,1-DIOXIDE DERIVATIVE OR PHARMACEUTICAL TOLERABLE SALTS AND THE PRESENT MATERIALS FOR USING THE PROCEDURE - Google Patents
METHOD OF ANALOGUE FOR THE PREPARATION OF THIENOOE2,3-EAA-1,2-THIAZIN-1,1-DIOXIDE DERIVATIVE OR PHARMACEUTICAL TOLERABLE SALTS AND THE PRESENT MATERIALS FOR USING THE PROCEDURE Download PDFInfo
- Publication number
- DK155009B DK155009B DK381283A DK381283A DK155009B DK 155009 B DK155009 B DK 155009B DK 381283 A DK381283 A DK 381283A DK 381283 A DK381283 A DK 381283A DK 155009 B DK155009 B DK 155009B
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- formula
- trifluoromethyl
- salts
- dioxide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
iin
DK 155009 BDK 155009 B
Den foreliggende opfindelse angår en analogifremgangsmåde til fremstilling af 4-hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-6-trifluormeth-yl-2H-thieno[2,3-e]-1,2-thiazin-1,1-dioxid med formlen IThe present invention relates to an analogous process for the preparation of 4-hydroxy-2-methyl-3- (2-pyridylcarbamoyl) -6-trifluoromethyl-2H-thieno [2,3-e] -1,2-thiazine-1, 1-dioxide of formula I
SOj /CH3SO₂ / CH3
--T--T
F3C S j^NCO—NH—^ \ IF3C S j ^ NCO — NH— ^ \ I
OH '-f eller farmaceutisk tolerable salte deraf.OH '- or pharmaceutically tolerable salts thereof.
5 Disse forbindelser er hidtil ukendte og udmærker sig ved at have værdifulde farmakodynamiske egenskaber.These compounds are novel and distinguishable by having valuable pharmacodynamic properties.
Den tilsvarende 6-chlor-forbindelse og den tilsvarende, ved thio-phenringen usubstituerede forbindelse er kendt fra henholdsvis EP-B 1.113 og DK P 137.835. I sammenligning med disse kendte forbindelser 10 udviser 6-trifluormethylforbindelsen, som fremstilles ved fremgangsmåden ifølge opfindelsen, en højere aktivitet og/eller et gunstigere forhold mellem ønskede og uønskede virkninger såsom toxicitet og/-eller ulcerogenitet.The corresponding 6-chloro compound and the corresponding unsubstituted compound in the thio-phen ring are known from EP-B 1.113 and DK P 137,835 respectively. Compared to these known compounds 10, the 6-trifluoromethyl compound produced by the process of the invention exhibits a higher activity and / or a more favorable ratio of desired and undesirable effects such as toxicity and / or ulcerogenicity.
Opfindelsen angår derfor en analogifremgangsmåde til fremstilling af 15 forbindelsen med formlen I eller farmaceutisk tolerable salte deraf samt mellemprodukter til deres fremstilling.The invention therefore relates to an analogous process for the preparation of the compound of formula I or pharmaceutically tolerable salts thereof and intermediates for their preparation.
I nærværende beskrivelse betegner udtrykket "lavere alkyl" ligekæ-dede eller forgrenede carbonhydridgrupper med 1-7 carbonatomer, fx methyl eller ethyl.As used herein, the term "lower alkyl" refers to straight-chain or branched hydrocarbon groups having 1-7 carbon atoms, for example, methyl or ethyl.
20 Fremgangsmåden ifølge opfindelsen er ejendommelig ved, at en forbindelse med den almene formel IIThe process of the invention is characterized in that a compound of the general formula II
22
DK 155009 BDK 155009 B
__Λ /“S__Λ / “S
χΥ jχΥ j
F3C S- ^ ^COORF3C S- ^ ^ COOR
OHOH
hvor R betegner lavere alkyl, omsættes med 2-aminopyridin, og den vundne forbindelse med formlen I om ønsket omdannes til et farmaceutisk tolerabelt salt deraf.wherein R represents lower alkyl, is reacted with 2-aminopyridine and the compound of formula I obtained is converted, if desired, to a pharmaceutically tolerable salt thereof.
Omsætningen ifølge opfindelsen kan foretages i nærværelse eller 5 fraværelse af et inert opløsningsmiddel. Som opløsningsmidler kan anvendes carbonhydrider, fx benzen, toluen eller xylen, halogenerede carbonhydrider, fx chloroform, chlorbenzen, methylenchlorid eller carbontetrachlorid, eller dimethylformamid eller dioxan. Omsætningen foretages fortrinsvis under opvarmning, fortrinsvis ved reaktions-10 blandingens tilbagesvalingstemperatur eller smeltetemperatur.The reaction of the invention may be carried out in the presence or absence of an inert solvent. Solvents can be used as solvents, for example benzene, toluene or xylene, halogenated hydrocarbons, for example chloroform, chlorobenzene, methylene chloride or carbon tetrachloride, or dimethylformamide or dioxane. The reaction is preferably carried out under heating, preferably at the reflux temperature of the reaction mixture or melting temperature.
Forbindelserne med formlen II er hidtil ukendte og udgør til anvendelse som udgangsmaterialer ved fremgangsmåden ifølge krav 1 et aspekt af den foreliggende opfindelse; de kan fx fremstilles ud fra forbindelser med den almene formel IIIThe compounds of formula II are novel and for use as starting materials in the process according to claim 1, an aspect of the present invention; they may be prepared, for example, from compounds of the general formula III
__ ri__ ri
F XOORF XOOR
IIIIII
15 hvor R har den ovenfor anførte betydning, hvilke forbindelser hører til en i sig selv kendt stofklasse, ifølge nedenstående reaktion s skema og det senere følgende specifikke eksempel.15 wherein R has the meaning given above, which compounds belong to a substance class per se, according to the scheme of the reaction below and the following specific example.
DK 155009 BDK 155009 B
33
Reaktionsskema _/nh3+ci" -/S°2CI n-S °2-nh i f —* i jT * jr3L ^Scheme _ / nh3 + ci + - / S ° 2Cl n-S ° 2-nh in f - * i jT * jr3L ^
F c/^S-^COOR F c^Ns^^COOR p COOR^COORF c / ^ S- ^ COOR F c ^ Ns ^^ COOR p COOR ^ COOR
3 3 3 III IV v .SO- β02 /CH33 3 3 III IV v .SO- β02 / CH3
_ nf T — JlCJ_ nf T - JlCJ
Ρ3<,^3^\|;^·νοοοπ p3c^'s^'y^S:oobΡ3 <, ^ 3 ^ \ |; ^ · νοοοπ p3c ^ 's ^' y ^ S: oob
OH OHOH OH
VI IIVI II
Forbindelsen med formlen I har et surt hydrogenatom og kan danne farmaceutisk tolerable salte med tilsvarende baser. Af sådanne salte kan fx nævnes alkalimetalsalte, fx lithium-, natrium- eller kaliumsalte; 5 jordal kalimetalsalte, fx magnesium- eller calciumsalte; samt salte med aminer såsom triethanolamin, diethylaminoethanol, triethylamin, tri-methylamin eller diethylamin. Forbindelsen med formlen I kan også danne farmaceutisk tolerable syreadditionssalte med stærke syrer, hvortil der især kan anvendes mineralsyrer såsom saltsyre.The compound of formula I has an acidic hydrogen atom and can form pharmaceutically tolerable salts with corresponding bases. Such salts include, for example, alkali metal salts, e.g., lithium, sodium or potassium salts; Alkaline earth metal salts, for example magnesium or calcium salts; and salts with amines such as triethanolamine, diethylaminoethanol, triethylamine, trimethylamine or diethylamine. The compound of formula I can also form pharmaceutically tolerable acid addition salts with strong acids to which mineral acids such as hydrochloric acid can be used.
10 Forbindelsen med formlen I samt salte deraf har antiinflammatoriske, analgetiske og antireumatiske virkninger. Disse værdifulde farmakologiske egenskaber kan bestemmes under anvendelse af standardmetoder, fx ved den kendte carrageenin-poteødemtest på rotter. I denne test fremkaldes en akut lokal betændelse i rottens højre bagpote ved 15 intradermal injektion af 0,1 ml af en 5%'s carrageeninopløsning. Det stof, der skal undersøges, administreres oralt, og potens diameter måles i mm (som udtryk for betændelsens heftighed).The compound of formula I and its salts have anti-inflammatory, analgesic and anti-rheumatic effects. These valuable pharmacological properties can be determined using standard methods, for example, in the known carrageenin paw edema test in rats. In this test, an acute local inflammation is induced in the right hind paw of the rat by intradermal injection of 0.1 ml of a 5% carrageenin solution. The substance to be examined is administered orally and the diameter of the pot is measured in mm (as an expression of the severity of the inflammation).
Efter carrageenininjektionen administreres det stof, der skal undersøges, og 2, 3 og 4 timer efter carrageenininjektionen måles potedia-20 meteren. Den ødemhæmmende virkning beregnes på grundlag af for- 4After the carrageenin injection, the substance to be examined is administered and 2, 3 and 4 hours after the carrageenin injection, the potadiometer is measured. The anti-edema effect is calculated on the basis of 4
DK 155009 BDK 155009 B
skellen i ødemintensitet mellem ubehandlede dyr og dyr, der er behandlet med det stof, der skal undersøges. ED3Q-Værdien er den dosis, som er nødvendig for at formindske diameteren af den ved carrageenin-injektion betændte pote med 30%. For forbindelsen med 5 formlen I er fundet en EDgQ-værdi på 1,91 mg/kg peroralt.the difference in desolation intensity between untreated animals and animals treated with the substance to be examined. The ED3Q value is the dose required to reduce the diameter of the paw inflamed by carrageenin injection by 30%. For the compound of formula I, an EDgQ value of 1.91 mg / kg was found orally.
Nedenfor er anført resultater af forsøg, der er udført med dels i forbindelsen med formlen I (R = CF^), dels de kendte forbindelser, i idet i den forbindelse, der er beskrevet i EP-B 1.113, R = Cl, og i den forbindelse, der er beskrevet i DK P 137.835, R^ = H.Listed below are results of experiments performed partly in the compound of formula I (R = CF 2) and partly in the known compounds, in the compound described in EP-B 1.113, R = Cl, and in the compound described in DK P 137,835, R
10 Forsøgsresultater __ ί s ϊ R^ V' C Λχ>-ΝΗ-< ).10 Test Results __ ί s ϊ R ^ V 'C Λχ> -ΝΗ- <).
OHOH
R1 A B C D X Y ZR1 A B C D X Y Z
CF3 1,91 250-500 13,3 0,09 6,96 130,89-261,78 195,94 15 Cl 2,01 312-625 2,42 0,11 1,20 155,22-310,95 233,09 H 3,22 312-625 44,2 4,1 13,73 96,89-194,10 145,50 A: Carrageen in-ødem, rotter, ED3q, mg/kg p.o.CF3 1.91 250-500 13.3 0.09 6.96 130.89-261.78 195.94 Cl 2.01 312-625 2.42 0.11 1.20 155.22-310.95 233.09 H 3.22 312-625 44.2 4.1 13.73 96.89-194.10 145.50 A: Carrageenan edema, rats, ED3q, mg / kg po
20 B: 3-dages-toxicitet, mus, LD^q, mg/kg p.o.B: 3-day toxicity, mouse, LD 2, mg / kg p.o.
C: Ulcerogenitet, rotter, UD^q, mg/kg p.o.C: Ulcerogenicity, rats, UD ^ q, mg / kg p.o.
D: Hæmning af fedtsyre-cyclooxygenase, IC^q, μΜ X: Kvotient UD^q (test C): ED^q (test A) Y: Kvotient LD^q (test B): ED^q (test A) 25 Z: Middelværdi af Y's grænseværdierD: Inhibition of fatty acid cyclooxygenase, IC ^ q, µΜ X: Quotient UD ^ q (test C): ED ^ q (test A) Y: quotient LD ^ q (test B): ED ^ q (test A) 25 Z: Mean value of Y's limit values
DK 155009 BDK 155009 B
55
Det fremgår af resultaterne, at forholdet C:A (jfr. X i tabellen med forsøgsresultater), dvs. forholdet mellem ulcerogenitet og ødemhæmmende virkning, er tydeligt gunstigere (næsten 6 gange) for trifluormethyI-forbindelsen end for chlorforbindelsen og kun lidt mere gunstig for trifluor-5 methyl-forbindelsen end for den usubstituerede forbindelse. Forholdet B:A (jfr. Y i tabellen med forsøgsresultater), dvs. forholdet mellem toxicitet og ødemhæmmende virkning, er noget gunstigere for trifluor-methyl-forbindelsen end for den usubstituerede forbindelse og kun uvæsentligt dårligere for trifluormethyl-forbindelsen end for chlorforbin-10 delsen.The results show that the ratio C: A (cf. X in the test results table), ie. the ratio of ulcerogenicity to edema inhibitory effect is clearly more favorable (almost 6 times) for the trifluoromethyl compound than for the chloro compound and only slightly more favorable for the trifluoromethyl compound than for the unsubstituted compound. Ratio B: A (cf. Y in the test results table), ie. the ratio of toxicity to edema inhibitory effect is somewhat more favorable for the trifluoromethyl compound than for the unsubstituted compound and only significantly worse for the trifluoromethyl compound than for the chloro compound.
Af de ovenfor diskuterede forhold fremgår det, at trifluormethyl-forbindelsen med formlen I har, alt efter hvilket kriterium der tages i betragtning, overlegen virkning i forhold til den tilsvarende chlorforbindelse og/eller den tilsvarende, ved thiophen-ringen usubstituerede forbindelse.From the conditions discussed above, it appears that the trifluoromethyl compound of formula I has, according to the criterion considered, superior effect to the corresponding chloro compound and / or the corresponding unsubstituted compound in the thiophene ring.
15 Forbindelsen med formlen I har en virkning, der kvalitativt ligner virkningen af phenylbutazon, som er kendt for sin terapeutiske anvendelse og egenskaber.The compound of formula I has an effect that is qualitatively similar to that of phenylbutazone, which is known for its therapeutic use and properties.
Forbindelsen med formlen I samt salte deraf kan anvendes som lægemiddel, fx i form af farmaceutiske præparater, som indeholder den i blanding med 20 et til enteral eller parenteral applikation egnet, farmaceutisk, organisk eller uorganisk inert bærestof, fx vand, gelatine, gummi arabicum, lactose, stivelse, magnesiumstearat, talkum, vegetabilske olier, polyalkylen-glycoler eller vaseline. De farmaceutiske præparater kan foreligge i fast form, fx som tabletter, dragéer, suppositorier eller kapsler, i halvfast 25 form, fx som salver, eller i flydende form, fx som opløsninger, suspensioner eller emulsioner. De er eventuelt steriliserede og/eller indeholder hjælpestoffer, fx konserveringsmidler, stabilisatorer eller emulgatorer, salte til ændring af det osmotiske tryk eller puffere. De kan også indeholde andre terapeutisk værdifulde stoffer.The compound of formula I and its salts may be used as a medicament, for example in the form of pharmaceutical compositions containing it in admixture with an enteric or parenteral application suitable pharmaceutical, organic or inorganic inert carrier, e.g., water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols or vaseline. The pharmaceutical compositions may be in solid form, for example as tablets, dragees, suppositories or capsules, in semi-solid form, for example as ointments, or in liquid form, for example as solutions, suspensions or emulsions. They are optionally sterilized and / or contain adjuvants, eg preservatives, stabilizers or emulsifiers, salts for changing the osmotic pressure or buffers. They may also contain other therapeutically valuable substances.
30 Som ovenfor omtalt kan forbindelsen med formlen I fremstillet ifølge opfindelsen og de farmaceutisk tolerable salte deraf anvendes til bekæmpelse eller forebyggelse af sygdomme, især til bekæmpelse eller forebyggelse af betændelser, smerter og reumatiske sygdomme. Doseringen af forbindelsen 6As mentioned above, the compound of formula I prepared according to the invention and the pharmaceutically tolerable salts thereof can be used for the control or prevention of diseases, especially for the control or prevention of inflammation, pain and rheumatic diseases. The dosage of the compound 6
DK 155009 BDK 155009 B
med formlen I og de farmaceutisk tolerable salte deraf kan varieres inden for temmelig vide grænser og skal naturligvis i hvert enkelt tilfælde tilpasses de individuelle forhold. Generelt skulle en oral daglig dosis på ca. 5 - ca. 100 mg, fortrinsvis ca. 10 - ca. 30 mg, være passende til et 5 menneske.of the formula I and the pharmaceutically tolerable salts thereof can be varied within rather wide limits and, of course, in each case must be adapted to the individual conditions. In general, an oral daily dose of approx. 5 - approx. 100 mg, preferably approx. 10 - approx. 30 mg, be appropriate for a 5 person.
Opfindelsen belyses nærmere i nedenstående eksempel.The invention is further illustrated in the example below.
EKSEMPELEXAMPLE
a) En opløsning af 172 g råt 3-amino-5-trifluormethylthiophen-2-carb-oxylsyreethylester-hydrochlorid [Monatshefte f. Chemie 105, 132 (1974)] i 10 lidt vand indstilles på alkalisk reaktion med natriumhydrogencarbonat, og det udfældede stof ekstraheres tre gange med hver gang 300 ml methylen-chlorid. De samlede organiske ekstrakter tørres over natriumsulfat og inddampes.a) A solution of 172 g of crude 3-amino-5-trifluoromethylthiophene-2-carboxylic acid ethyl ester hydrochloride [Monatshefte f. Chemie 105, 132 (1974)] in a little water is adjusted to alkaline reaction with sodium hydrogen carbonate and the precipitated substance extracted three times with 300 ml of methylene chloride each time. The combined organic extracts are dried over sodium sulfate and evaporated.
Til den således vundne frie base (102 g) sættes en opløsning af 2 g 15 natrium i 800 ml absolut methanol, og den vundne opløsning opvarmes til kogning under tilbagesvaling i 40 minutter. Efter afkøling tilsættes 6 ml iseddike, methanolet fjernes i vid udstrækning i vakuum, og remanensen fordeles mellem methylenchlorid og mættet natriumhydrogencarbonatopløs-ning. Den organiske fase fraskilles, tørres over natriumsulfat og inddam-20 pes. Den olieagtige remanens inddampes yderligere to gange med noget benzen til fjernelse af resterende methylenchlorid og optages derefter i 600 ml absolut benzen. Til opløsningen sættes 3 teskefulde aktivkul, der frasuges, og der tilledes tør hydrogenchloridgas, indtil der er opnået fuldstændig udfældning. Det farveløse krystallinske 3-amino-5-trifluorme-25 thylthiophen-2-carboxylsyremethylester-hydrochlorid frasuges, vaskes med benzen og tørres i luften.To the free base thus obtained (102 g) is added a solution of 2 g of sodium in 800 ml of absolute methanol, and the obtained solution is heated to reflux for 40 minutes. After cooling, 6 ml of glacial acetic acid is added, the methanol is largely removed in vacuo and the residue partitioned between methylene chloride and saturated sodium hydrogen carbonate solution. The organic phase is separated, dried over sodium sulfate and evaporated. The oily residue is further evaporated twice with some benzene to remove residual methylene chloride and then taken up in 600 ml of absolute benzene. To the solution are added 3 teaspoons of activated charcoal, which is aspirated, and dry hydrogen chloride gas is added until complete precipitation is obtained. The colorless crystalline 3-amino-5-trifluoromethyl-thiophene-2-carboxylic acid methyl ester hydrochloride is aspirated, washed with benzene and dried in the air.
b) 5,60 g (0,0217 mol) 3-amino-5-trifluormethylthiophen-2-carboxylsyreme-thylester-hydrochlorid optages portionsvis ved -2°C og under omrøring i 11,3 ml koncentreret saltsyre, hvorved der dannes en tyk grød. Derefter 30 tilledes ved mellem -5 og 0°C en opløsning af 1,51 g natriumnitrit i 2,7 ml vand i løbet af 1 1/2 time under suspensionens overflade, idet reaktions-b) 5.60 g (0.0217 mol) of 3-amino-5-trifluoromethylthiophene-2-carboxylic acid methyl ester hydrochloride are taken up portionwise at -2 ° C and with stirring in 11.3 ml of concentrated hydrochloric acid to form a thick porridge. Thereafter, a solution of 1.51 g of sodium nitrite in 2.7 ml of water over 1 1/2 hours under the surface of the suspension is added at between -5 and 0 ° C,
DK 155009 BDK 155009 B
7 blandingen hen imod slutningen af tilsætningen bliver tyndtflydende. Der omrøres i yderligere 1 time ved -3°C, hvorefter opløsningen af det vund-ne diazoniumsalt på én gang sættes til en blanding af 2,4 ml mættet kobber-(ll)-chloridopløsning og 38 ml 30%'s svovldioxidopløsning i ised-5 dike, hvorved der straks indtræder heftig opskumning. Der omrøres i yderligere 1 time ved stuetemperatur, hvorefter blandingen hældes på 70 ml isvand, og den udfældede olie ekstraheres fem gange med hver gang 50 ml methylenchlorid. De samlede organiske ekstrakter vaskes tre gange med hver gang 25 ml vand, tørres over natriumsulfat og inddampes i 10 vakuum. Den olieagtige remanens bestående af 3-chlorsulfonyl-5-trifluor-methylthiophen-2-carboxylsyre-methylester anvendes til næste reaktionstrin uden yderligere rensning.The mixture towards the end of the addition becomes thin liquid. Stir for a further 1 hour at -3 ° C, after which the solution of the obtained diazonium salt is added at once to a mixture of 2.4 ml of saturated copper (II) chloride solution and 38 ml of 30% sulfur dioxide solution in ice. -5 dike, which immediately causes severe foaming. Stir for an additional 1 hour at room temperature, after which the mixture is poured onto 70 ml of ice water and the precipitated oil is extracted five times with 50 ml of methylene chloride each time. The combined organic extracts are washed three times with 25 ml of water each time, dried over sodium sulfate and evaporated in vacuo. The oily residue consisting of 3-chlorosulfonyl-5-trifluoro-methylthiophene-2-carboxylic acid methyl ester is used for the next reaction step without further purification.
c) 103,8 g (0,336 mol) 3-chlorsulfonyl-5-trifluormethylthiophen-2-carb-oxylsyre-methylester optages i 600 ml chloroform, og der tildryppes 68,05 15 g (0,765 mol) frisk destilleret glycinmethylester på en sådan måde, at temperaturen ikke overstiger 30°C, hvorefter der omrøres i yderligere 0,5 time ved stuetemperatur, og rekationsblandingen udrystes tre gange med hver gang 200 ml IN saltsyre. Den organiske fase tørres over natriumsulfat og inddampes. Den olieagtige remanens udrøres med 175 ml diiso-20 propylether, hvorved der fås 3-[(methoxycarbonylmethyl)sulfamoyl]-5-tri-fluormethylthiophen-2-carboxylsyre-methylester i form af farveløse krystaller, som frasuges og vaskes med diisopropylether. Efter omkrystallisation af diisopropylether smelter produktet ved 76-78°C.c) 103.8 g (0.336 mole) of 3-chlorosulfonyl-5-trifluoromethylthiophene-2-carboxylic acid methyl ester are taken up in 600 ml of chloroform and 68.05 g (0.765 mole) of freshly distilled glycine methyl ester are added in such a manner Make sure the temperature does not exceed 30 ° C, then stir for an additional 0.5 hours at room temperature and shake the reaction mixture three times with 200 ml of 1 N hydrochloric acid each time. The organic phase is dried over sodium sulfate and evaporated. The oily residue is stirred with 175 ml of diisopropyl ether to give 3 - [(methoxycarbonylmethyl) sulfamoyl] -5-trifluoromethylthiophene-2-carboxylic acid methyl ester in the form of colorless crystals which are extracted and washed with diisopropyl ether. After recrystallization from diisopropyl ether, the product melts at 76-78 ° C.
d) En opløsning af 82,8 g (0,229 mol) 3-[(methoxycarbonylmethyl)sul-25 famoyl]-5-trifluormethylthiophen-2-carboxylsyre-methylester i 1,7 liter absolut tetrahyd rof uran afkøles til 3°C, og ved denne temperatur sættes der i løbet af 20 minutter portionsvis i alt 62,9 g (0,562 mol) kalium-tert.butylat. Derefter fjernes kølebadet, den tyktflydende røde grød omrøres i 2 timer ved stuetemperatur, hvorefter der ved højst 30°C i 30 vakuum afdestilleres så meget tetrahyd rof uran som muligt. Den pulver-agtige remanens optages i 1,4 liter isvand, tilsættes under omrøring 10 g aktivkul og afsuges over kiselgur. Filtratet indstilles på pH-værdi 2-3 med ca. 185 ml 3N saltsyre ved højst 5°C. Der omrøres i 0,5 time, hvorved det i starten olieagtigt forekommende råprodukt krystalliserer (efter 35 tilsætning af noget ether). Det udfældede råprodukt frasuges, vaskes 8d) A solution of 82.8 g (0.229 mol) of 3 - [(methoxycarbonylmethyl) sulfamoyl] -5-trifluoromethylthiophene-2-carboxylic acid methyl ester in 1.7 liters of absolute tetrahydric uranium is cooled to 3 ° C, and at this temperature, a total of 62.9 g (0.562 mole) of potassium tert.butylate is added portionwise over 20 minutes. Then the cooling bath is removed, the viscous red porridge is stirred for 2 hours at room temperature, and at as much as 30 ° C in 30 vacuum, as much tetrahydro-uranium as possible is distilled off. The powdery residue is taken up in 1.4 liters of ice water, added with stirring 10 g of activated charcoal and suctioned over diatomaceous earth. The filtrate is adjusted to pH 2-3 with approx. 185 ml of 3N hydrochloric acid at a maximum of 5 ° C. The mixture is stirred for 0.5 hour, whereby the crude oily product initially crystallizes (after the addition of some ether). The precipitated crude product is aspirated, washed 8
DK 155009 BDK 155009 B
neutralt med vand, tørres natten over i vakuum ved 50°C og omkrystalliseres af methanol. Der fås 4-hydroxy-3-methoxycarbonyl-6-trifluormeth-yI-2H-thieno[2,3-e]-1,2-thiazin-1,1-dioxid, smeltepunkt 168-170°C.neutral with water, dried overnight in vacuo at 50 ° C and recrystallized from methanol. There is obtained 4-hydroxy-3-methoxycarbonyl-6-trifluoromethyl-2H-thieno [2,3-e] -1,2-thiazine-1,1-dioxide, m.p. 168-170 ° C.
e) Til en til -2°C afkølet opløsning af 5,65 g (0,0172 mol) 4-hydroxy~3-5 methoxycarbonyl-6-trifluormethyl-2H-thieno[2,3-e]-1,2-thiazin-1,1 -dioxid i 62 ml absolut dimethylformamid sættes under kraftig nitrogenstrøm portionsvis 0,87 g (0,0362 mol) natriumhydrid (vasket med benzen), der omrøres i yderligere 1 1/2 time ved 5°C, hvorefter blandingen på én gang tilsættes 1,49 ml (0,024 mol) methyliodid, hvorved temperaturen stiger til 10 ca. 5°C, og der omrøres i yderligere 1 1/2 time ved stuetemperatur og inddampes derpå i vakuum. Remanensen fordeles mellem 2N saltsyre og methylenchlorid, den vandige fase udrystes yderligere tre gange med methylenchlorid, og de samlede organiske ekstrakter tørres over natriumsulfat og inddampes. Den brune krystallinske remanens digereres med 15 ca. 50 ml ethanol, og de næsten farveløse krystaller frasuges og vaskes med methanol. Efter omkrystallisation af ethanol fås 4-hydroxy-3-meth-oxycarbonyl-2-methyl-6-trifluormethyl-2H-thieno[2,3-e] -1,2-thiazin-l, 1 -dioxid, smeltepunkt 178-180°C.e) To a solution cooled to -2 ° C of 5.65 g (0.0172 mol) of 4-hydroxy-3-5 methoxycarbonyl-6-trifluoromethyl-2H-thieno [2,3-e] -1,2- Thiazine-1,1-dioxide in 62 ml of absolute dimethylformamide is added to vigorous 0.87 g (0.0362 mole) of sodium hydride (washed with benzene) stirred vigorously for a further 1 1/2 hours at 5 ° C, after which the mixture is stirred. at one time 1.49 ml (0.024 mol) of methyl iodide is added, raising the temperature to about 10 ml. 5 ° C and stirred for an additional 1 1/2 hours at room temperature and then evaporated in vacuo. The residue is partitioned between 2N hydrochloric acid and methylene chloride, the aqueous phase is further shaken three times with methylene chloride and the combined organic extracts are dried over sodium sulfate and evaporated. The brown crystalline residue is digested with approx. 50 ml of ethanol and the almost colorless crystals are extracted and washed with methanol. After recrystallization from ethanol, 4-hydroxy-3-methoxycarbonyl-2-methyl-6-trifluoromethyl-2H-thieno [2,3-e] -1,2-thiazine-1,1-dioxide is obtained, m.p. 178-180 ° C.
f) 4,25 g (0,0124 mol) 4-hydroxy-3-methoxycarbony!-2-methyl-6-trifluor-20 methyl-2H-thieno[2,3-e]-1,2-thiazin-1,1 -dioxid opvarmes til kogning under tilbagesvaling under omrøring sammen med 1,54 g (0,0163 mol) 2-amino-pyridin i 192 ml xylen i 5 timer, hvorhos opløsningsmidlet langsomt afdes-tilleres og suppleres med frisk xylen. Der inddampes derefter i vakuum, den halvkrystallinske remanens digereres i ca. 40 ml dioxan, og de vund-25 ne gule krystaller frasuges og vaskes med dioxan. Råproduktet fordeles mellem 30 ml methylenchlorid og 40 ml vand, som indeholder 3 ml 10%'s natriumhydroxidopløsning, faserne adskilles, til den vandige fase sættes 0,5 g aktivkul, og der filtreres gennem kiselgur, og filtratet opvarmes til 30°C og indstilles på pH-værdi 2 med ca. 2,7 ml 3N saltsyre (under 30 omrøring i 1 time). De udfældede gule, fine krystaller frasuges, vaskes med rigeligt vand og tørres i 8 timer i høj vakuum (0,1 mm Hg) ved 105°C. Der fås 4-hydroxy-2-methyl-3-(2-pyridylcarbamoyl)-6-trifluormeth-yl-2H-thieno[2,3-e]-1,2-thiazin-1,1-dioxid, smeltepunkt 230°C (sønderdeling).f) 4.25 g (0.0124 mol) of 4-hydroxy-3-methoxycarbonyl-2-methyl-6-trifluoro-methyl-2H-thieno [2,3-e] -1,2-thiazine-1 1-Dioxide is heated to reflux with stirring together with 1.54 g (0.0163 mole) of 2-amino-pyridine in 192 ml of xylene for 5 hours, whereupon the solvent is slowly evaporated and supplemented with fresh xylene. It is then evaporated in vacuo, the semicrystalline residue digested for approx. 40 ml of dioxane and the yellow crystals obtained are extracted and washed with dioxane. The crude product is partitioned between 30 ml of methylene chloride and 40 ml of water containing 3 ml of 10% sodium hydroxide solution, the phases are separated, the aqueous phase is added 0.5 g of activated charcoal and filtered through diatomaceous earth and the filtrate is heated to 30 ° C and adjusted at pH 2 with approx. 2.7 ml of 3N hydrochloric acid (with stirring for 1 hour). The precipitated yellow, fine crystals are aspirated, washed with plenty of water and dried for 8 hours in high vacuum (0.1 mm Hg) at 105 ° C. 4-hydroxy-2-methyl-3- (2-pyridylcarbamoyl) -6-trifluoromethyl-2H-thieno [2,3-e] -1,2-thiazine-1,1-dioxide, m.p. 230 ° C (decomposition).
Claims (2)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH537782 | 1982-09-09 | ||
| CH537782 | 1982-09-09 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| DK381283D0 DK381283D0 (en) | 1983-08-19 |
| DK381283A DK381283A (en) | 1984-03-10 |
| DK155009B true DK155009B (en) | 1989-01-23 |
| DK155009C DK155009C (en) | 1989-06-05 |
Family
ID=4292544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK381283A DK155009C (en) | 1982-09-09 | 1983-08-19 | METHOD OF ANALOGUE FOR THE PREPARATION OF THIENOOE2,3-EAA-1,2-THIAZIN-1,1-DIOXIDE DERIVATIVE OR PHARMACEUTICAL TOLERABLE SALTS AND THE PRESENT MATERIALS FOR USING THE PROCEDURE |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4544655A (en) |
| EP (1) | EP0103142B1 (en) |
| JP (1) | JPS5967292A (en) |
| AT (1) | ATE26720T1 (en) |
| AU (1) | AU560973B2 (en) |
| CA (1) | CA1217187A (en) |
| DE (1) | DE3371082D1 (en) |
| DK (1) | DK155009C (en) |
| IE (1) | IE55942B1 (en) |
| IL (1) | IL69628A (en) |
| NZ (1) | NZ205475A (en) |
| PH (1) | PH19692A (en) |
| ZA (1) | ZA836546B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ226477A (en) * | 1987-10-29 | 1990-07-26 | Cl Pharma | Substituted thieno (2,3-e)-1,2 thiazine derivatives and pharmaceutical compositions |
| ATA39088A (en) | 1988-02-18 | 1990-06-15 | Binder Dieter Dr | BASICALLY SUBSTITUTED THIENOISOTHIAZOL-3 (2H) -ON-1,1-DIOXIDES AND THEIR PHARMACEUTICALLY COMPATIBLE SALTS, METHOD FOR THE PRODUCTION AND THEIR USE |
| AT399880B (en) * | 1992-07-03 | 1995-08-25 | Chem Pharm Forsch Gmbh | NEW THIENOTHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
| EP0658559A1 (en) * | 1993-12-14 | 1995-06-21 | Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. | Thienothiazin derivatives, process for their preparation and their use as 5-dipoxygenase and cyclooxygenase inhibitors |
| US8329924B2 (en) * | 2001-06-11 | 2012-12-11 | Vertex Pharmaceuticals (Canada) Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
| JP4544857B2 (en) * | 2001-06-11 | 2010-09-15 | ヴァイロケム ファーマ インコーポレイテッド | Compounds and methods for the treatment or prevention of FLAVIRIRUS infection |
| AT413944B (en) | 2003-05-27 | 2006-07-15 | Binder Eva Dkfm | USE OF OXICAM COMPOUNDS |
| US7109232B2 (en) * | 2004-03-08 | 2006-09-19 | Simpson Biotech Co., Ltd. | Compounds from Antrodia camphorata having anti-inflammatory and anti-tumor activity |
| CN105384676B (en) * | 2008-12-16 | 2019-05-07 | 桑诺维恩药品公司 | Triple reuptaking inhibitors and its application method |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1066711A (en) * | 1974-08-26 | 1979-11-20 | Hoffmann-La Roche Limited | Thiophene derivatives |
| IL47877A (en) * | 1974-08-26 | 1978-10-31 | Sparamedica Ag | Thienothiazine carboxamide derivatives,their manufacture and pharmaceutical compositions containing them |
| AU518216B2 (en) * | 1977-09-06 | 1981-09-17 | Hafslund Nycomed Pharma Aktiengesellschaft | Thienothiazine derivatives |
-
1983
- 1983-08-04 AT AT83107677T patent/ATE26720T1/en not_active IP Right Cessation
- 1983-08-04 DE DE8383107677T patent/DE3371082D1/en not_active Expired
- 1983-08-04 EP EP83107677A patent/EP0103142B1/en not_active Expired
- 1983-08-12 CA CA000434462A patent/CA1217187A/en not_active Expired
- 1983-08-19 DK DK381283A patent/DK155009C/en not_active IP Right Cessation
- 1983-08-31 US US06/528,341 patent/US4544655A/en not_active Expired - Fee Related
- 1983-09-02 ZA ZA836546A patent/ZA836546B/en unknown
- 1983-09-02 IL IL69628A patent/IL69628A/en unknown
- 1983-09-02 NZ NZ205475A patent/NZ205475A/en unknown
- 1983-09-06 JP JP58162711A patent/JPS5967292A/en active Pending
- 1983-09-08 IE IE2108/83A patent/IE55942B1/en unknown
- 1983-09-09 PH PH29520A patent/PH19692A/en unknown
- 1983-09-09 AU AU19007/83A patent/AU560973B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5967292A (en) | 1984-04-16 |
| ZA836546B (en) | 1984-04-25 |
| AU560973B2 (en) | 1987-04-30 |
| PH19692A (en) | 1986-06-13 |
| AU1900783A (en) | 1984-03-15 |
| DK155009C (en) | 1989-06-05 |
| DK381283D0 (en) | 1983-08-19 |
| DE3371082D1 (en) | 1987-05-27 |
| EP0103142A1 (en) | 1984-03-21 |
| IL69628A0 (en) | 1983-12-30 |
| ATE26720T1 (en) | 1987-05-15 |
| IE832108L (en) | 1984-03-09 |
| NZ205475A (en) | 1985-08-30 |
| EP0103142B1 (en) | 1987-04-22 |
| CA1217187A (en) | 1987-01-27 |
| US4544655A (en) | 1985-10-01 |
| IL69628A (en) | 1986-09-30 |
| IE55942B1 (en) | 1991-02-27 |
| DK381283A (en) | 1984-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2129549C1 (en) | Pyrimidine derivatives and methods of preparing thereof | |
| DK148280B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THIENOTHIAZINE DERIVATIVES | |
| JPH07267964A (en) | New n-heterocyclic thienothiazinecarboxamide, its productionand its use | |
| PL115756B1 (en) | Process for preparing novel 1,1-dioxid-4-hydroxy-2h-1,2-benzothiazin-3-carboxyamides | |
| US3962261A (en) | 2,3,4,5-tetra hydro-5-oxo-1-benzothiepi n-4-carboxamide 1,1-dioxides | |
| US4224445A (en) | Thienothiazine derivatives | |
| PL106076B1 (en) | METHOD OF MAKING NEW THENOTHIAZINE DERIVATIVES | |
| DK155009B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF THIENOOE2,3-EAA-1,2-THIAZIN-1,1-DIOXIDE DERIVATIVE OR PHARMACEUTICAL TOLERABLE SALTS AND THE PRESENT MATERIALS FOR USING THE PROCEDURE | |
| NO743186L (en) | ||
| CA1243318A (en) | Process for preparing 4-(isoxazolyl)-thiazole-2- oxamic acid derivatives | |
| CA1312870C (en) | Alkanesulfonamides as antiglaucoma agents | |
| US4187303A (en) | Thiazine derivatives | |
| US3530137A (en) | Certain alkyl and aryl ethers and thioethers of tropine and derivatives thereof | |
| DK172034B1 (en) | 4-OH-quinoline carboxylic acid derivatives, their preparation, intermediates in their preparation, and drugs containing them | |
| US4090020A (en) | Thienothiazine derivatives | |
| DK170047B1 (en) | Substituted with basic heterocyclic groups 5-halo-thienoisothiazole-3 (2H) -one-1,1-dioxides and salts thereof, process for the preparation of such compounds, pharmaceutical compositions containing these compounds and the use of the compounds in the preparation of drugs for the treatment of anxiety states | |
| US3303191A (en) | Novel 4-ketodihydro-2, 1-benzothiazine-2, 2-dioxides | |
| US4177193A (en) | Thienothiazine derivatives | |
| US4348519A (en) | Thiazine derivatives | |
| US4134898A (en) | N-Carbalkoxymethylsulfamoyl thiophene carboxylic acid alkyl esters | |
| NO830611L (en) | IMIDAZOTIADIAZOLALKENCARBOXYLIC ACID AMIDES, NEW INTERMEDIATES FOR THEIR PREPARATION, THEIR PREPARATION AND THEIR USE IN PHARMACEUTICALS | |
| SU898956A3 (en) | Method of preparing benzo (b) thiophene-2 derivatives or their salts | |
| PL146350B1 (en) | Method of obtaining oxazine(5,6-c)1,2-benzothiazine | |
| DK157683B (en) | METHOD OF ANALOGUE FOR PREPARING A BENZOQUINOLIZIN DERIVATIVE OR A PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALT | |
| PT94904A (en) | METHOD FOR PREPARING BENZOTIAZIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |